Trial · NCT07897409
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
NCT07897409, Phase 2, Not yet recruiting, Universiti Sains Malaysia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity. Trials, record NCT07897409. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897409
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
- NCT number
- NCT07897409
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 146 participants, estimated
- Lead sponsor
- Universiti Sains Malaysia
- Conditions
- Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy, Doxorubicin, Doxorubicin Adverse Reaction
- Interventions
- Nicorandil Oral Tablet, Adriamycin (Doxorubicin)
- First posted
- 2026-10-27
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To evaluate the effect of nicorandil on left ventricular ejection fraction in breast cancer patients receiving doxorubicin. | before the treatment initiation, at the 3rd and the 6th months of the treatment initiation | Elevation or maintenance of Ejection fraction percentage (EF %) using echocardiogram |
| Primary | To evaluate the safety of nicorandil | before the treatment initiation, at the 3rd and the 6th months of the treatment initiation | possible hypotension (mmhg) |
| Secondary | To assess patients' quality of life | From enrollment, at the 3rd and the 6th months of the treatment | using the modified EORTC QLQ-BR42, where 100 is the best quality and 0 is the worst. |
| Secondary | To determine the effect of nicorandil on global longitudinal strain in breast cancer patients receiving doxorubicin. | From enrollment and at the 3rd and the 6th months of treatment | by using echogradiogram in % |
| Secondary | To evaluate the cost-utility of nicorandil as a cardioprotective agent against doxorubicin-induced cardiotoxicity. | at the treatment initiation, the 3rd and the 6th months of the treament | using the QALY unit |
| Secondary | To assess the effect of nicorandil on cardiac biomarkers | at the treatment initiation, at the 3rd and 6th months of the treament | by assessing, including cardiac troponin ng/ml |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897409
GET https://conductscience.org/api/trials/v1/NCT07897409/registered